Technetium Tc 99m apcitide is a radiopharmaceutical containing a metastable nuclear isomer of technetium-99. Upon radioactive decay with a half-life of 6 hours gamma-rays which can be detected using conventional equipment for X-ray diagnostics. Tc 99m contains the small-molecule synthetic peptide apcitide which binds to the PIIb/IIIa receptors on the surface of activated platelets, which are a major component in active thrombus formation. The localization of radioactivity may be recorded by gamma-ray detection camera. Tc 99m apcitide is indicated for scintigraphic imaging of acute venous thrombosis in the lower extremities in patients with signs and symptoms of acute blood clots. It is marketed by Bayer under tradename AcuTect.

Iobenguane I-131 is a radioactive therapeutic agent. The drug contains radioactive isotope I-131, which decays by electron emission with a half-life of about 8 days. By the chemical structure, iobenguane is similar to the neurotransmitter norepinephrine and is subject to the same uptake and regulation pathways. After intravenous administration, iobenguane I-131 accumulates within pheochromocytoma and paraganglioma cells, and radiation from the radioactive decay causes cell death and tumor necrosis. Iobenguane I-131 was approved by the FDA for the treatment of adult and pediatric patients with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Iobenguane I-131 is investigated in clinical trials as a treatment of neuroblastoma, ganglioneuroblastoma and other tumors of neuroendocrinal origin.

Cyanocobalamin Co-58 is radiopharmaceutical derivative of an essential vitamin B12. Radioactive isotope Co-58 has a half-life of 72 days and produces hard gamma radiation when it decays to Fe-58. In the 1960s, cyanocobalamin Co-58 was used in western European countries for the diagnosis of liver diseases: hepatitis, parenchymal liver disease, lead poisoning, and other condition. Its use was superseded by cyanocobalamin Co-57, which is marketed used for the diagnosis of pernicious anemia and as a diagnostic adjunct in other defects of intestinal vitamin B12 absorption.

Cyanocobalamin Co 57 is a manufactured form of radiolabeled vitamin B indicated as an adjunct in diagnosing intestinal cyanocobalamin malabsorption syndromes due to lack of intrinsic factor (IF) or other defects in intestinal absorption (e.g., blind loop syndrome and diverticulitis, celiac disease, Crohn's disease, lesions in the small intestine, severe pancreatitis, tropical sprue).

Radioactive L-Selenomethionine in which the sulfur atom in the methionine has been replaced by selenium. The compound is used intravenously to investigate methionine metabolism and as diagnostic aid in pancreas function determination.

IODOHIPPURIC ACID I-131 (ortho-Iodohippuric Acid I-131, [I-123]-OIH) is an iodine-containing compound used in pyelography as a radiopaque medium. Iodine-123 labelled ortho-Iodohippuric acid was used in the early 1970's as a kidney imaging agent or tracer that "lights-up" inside your body when scanned, but over the years its use has declined. [I-123]-OIH is primarily extracted by the renal tubules and has excellent pharmacokinetic properties, with a clearance only slightly less than that of p-aminohippuran, but its use has been compromised by the suboptimal imaging characteristics of the 364-keV photon of 131I and the delivery of relatively high radiation doses to kidneys and thyroid in patients with impaired renal function

Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60. Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US by unknown reasons.

[123I]Iomazenil ([123I] IMZ) is a ligand displaying high affinity for central-type benzodiazepine receptors. It is a useful marker of neuronal viability. [123I]IMZ has been successfully used as a probe for single photon emission computed tomography (SPECT) in numerous clinical studies of diseases and also itcan be used to image epileptic seizure foci. 123I-iomazenil is rapidly metabolized and more than 90% of the administrated radioactivity was excreted within the first 24 hr. Dominant metabolites were acid metabolite (R-COOH), glucuronide of the acid (R-COOH-Glc) and free iodide (I-). Metabolites of 123I-iomazenil do not cross the blood-brain barrier. [123I]IMZ is readily available commercially.